The Zika virus is a mosquito-borne pathogen that has been implicated in a number of grave complications to fetuses carried by infected women. More recently, Zika has been linked to a spike in the number of cases of Guillain-Barre syndrome and microcephaly, a condition in which babies have severely hindered brain development and are born with smaller heads. Given this possible link to these serious birth defects, there is a pressing need for a way to definitively diagnose whether a woman has been exposed to the virus. Current methods to test for the presence of Zika miss the narrow time window before the virus clears the body after infection and serological tests are often hindered by cross-reactivity to other flaviviruses endemic in the same regions as Zika. The studies described here propose the development of an immunoassay targeting only those antibodies in the host?s polyclonal response that bind to those epitopes in the Zika coat protein that are not shared by other Flaviviruses. Such an assay could lead to more clinically specific immunoassays for the viruses in question. First we will develop novel computationally designed hyperstable viral epitope mimetics (VEMs) of the Zika envelope protein with structures that can specifically bind human anti-Zika immunoglobulins. Second these VEMs will be implemented in a rapid, low-cost paper-based sandwich immunoassay capable of detecting anti-Zika antibodies in human plasma at clinically relevant concentrations.

Public Health Relevance

The recent Zika virus epidemic has caused concern worldwide, largely due to the link between the mosquito-born pathogen and a number of severe complications to fetuses carried by infected women. Current methods to test for presence of this virus are slow and often hindered by cross-reactivity to other viruses suggesting a pressing need for a way to rapidly and specifically test for Zika virus exposure. This project focuses on the computational design of novel viral epitope mimetics of the Zika envelope protein to be implemented in a low-cost instrument-free paper-based assay.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21AI128950-01
Application #
9252180
Study Section
Special Emphasis Panel (ZAI1-AZ-M (S2))
Program Officer
Challberg, Mark D
Project Start
2016-08-20
Project End
2018-07-31
Budget Start
2016-08-20
Budget End
2017-07-31
Support Year
1
Fiscal Year
2016
Total Cost
$221,788
Indirect Cost
$71,788
Name
University of Washington
Department
Biochemistry
Type
Schools of Medicine
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195